scholarly article | Q13442814 |
P2093 | author name string | Karlheinz Friedrich | |
Raoudha Doghri | |||
Karima Mrad | |||
Ridha Oueslati | |||
Manel Khemiri | |||
P2860 | cites work | Mucins in cancer: function, prognosis and therapy | Q24633765 |
Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease | Q26753174 | ||
Prognostic Significance of Mucin Antigen MUC1 in Various Human Epithelial Cancers: A Meta-Analysis | Q26774725 | ||
Cytokines, IBD, and colitis-associated cancer | Q28080901 | ||
Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut | Q28081848 | ||
Inflammatory bowel disease | Q29615500 | ||
Genetics and pathogenesis of inflammatory bowel disease | Q29616350 | ||
Inflammatory bowel disease: an expanding global health problem | Q33608406 | ||
Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis | Q33811691 | ||
MUC1: a multifaceted oncoprotein with a key role in cancer progression | Q33880143 | ||
Effect of pro-inflammatory mediators on membrane-associated mucins expressed by human ocular surface epithelial cells | Q33894453 | ||
Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors | Q34257652 | ||
Mucin-bacterial interactions in the human oral cavity and digestive tract | Q34503629 | ||
Altered glycosylation in inflammatory bowel disease: a possible role in cancer development | Q35160089 | ||
The expression and significance of Gal-3 and MUC1 in colorectal cancer and colon cancer | Q35915348 | ||
Differentiation therapy: a promising strategy for cancer treatment | Q36439681 | ||
Inflammation and colon cancer | Q37737408 | ||
Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. | Q37885729 | ||
Mucins in inflammatory bowel diseases and colorectal cancer | Q37931346 | ||
Intestinal barrier homeostasis in inflammatory bowel disease. | Q38293757 | ||
Immunohistochemical study of MUC1, MUC2 and MUC5AC in colorectal carcinoma and review of literature | Q38366747 | ||
The role of the mediators of inflammation in cancer development. | Q38367696 | ||
The global burden of IBD: from 2015 to 2025. | Q38577572 | ||
Emerging cytokine networks in colorectal cancer. | Q38584430 | ||
Interleukin-6 (IL-6) released by macrophages induces IL-6 secretion in the human colon cancer HT-29 cell line | Q39875367 | ||
Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer | Q39999722 | ||
The MUC1 SEA module is a self-cleaving domain. | Q40403573 | ||
Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies | Q41839859 | ||
Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study | Q47631911 | ||
Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma | Q74096490 | ||
Quantification of histochemical staining by color deconvolution | Q74448733 | ||
Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer | Q80582113 | ||
[Expression and clinical significance of Mucin and E-cadherin in colorectal tumors] | Q81572363 | ||
Aberrant expression of MUC1 mucin in pediatric inflammatory bowel disease | Q82688588 | ||
P4510 | describes a project that uses | ImageJ | Q1659584 |
P433 | issue | 5 | |
P921 | main subject | colorectal cancer | Q188874 |
inflammatory bowel diseases | Q917447 | ||
P304 | page(s) | 1731-1737 | |
P577 | publication date | 2019-05-01 | |
P1433 | published in | International Journal of Clinical and Experimental Pathology | Q6051341 |
P1476 | title | Mucin-1 expression and localization in epithelial cells shows characteristic and distinct patterns in inflammatory bowel diseases and colorectal cancer | |
P478 | volume | 12 |
Search more.